Coronavirus disease 2019 (COVID-19) pharmacologic treatments for children : research priorities and approach to pediatric studies

Simple item page
dc.contributor.authorGarcia-Prats, Anthony J.en_ZA
dc.contributor.authorSalazar-Austin, Nicoleen_ZA
dc.contributor.authorConway, James H.en_ZA
dc.contributor.authorRadtke, Kendraen_ZA
dc.contributor.authorLaCourse, Sylvia M.en_ZA
dc.contributor.authorMaleche-Obimbo, Elizabethen_ZA
dc.contributor.authorHesseling, Anneke C.en_ZA
dc.contributor.authorSavic, Rada M.en_ZA
dc.contributor.authorNachman, Sharonen_ZA
dc.date.accessioned2022-06-01T14:09:00Zen_ZA
dc.date.available2022-06-01T14:09:00Zen_ZA
dc.date.issued2020-06en_ZA
dc.descriptionCITATION: Garcia-Prats, A. J. et al. 2021. Coronavirus Disease 2019 (COVID-19) Pharmacologic Treatments for Children: Research Priorities and Approach to Pediatric Studies. Clinical infectious diseases, 72(6):1067–1073. doi:10.1093/cid/ciaa885en_ZA
dc.descriptionThe original publication is available at https://academic.oup.com/cid/en_ZA
dc.description.abstractClinical trials of pharmacologic treatments of coronavirus disease 2019 (COVID-19) are being rapidly designed and implemented in adults. Children are often not considered during development of novel treatments for infectious diseases until very late. Although children appear to have a lower risk compared with adults of severe COVID-19 disease, a substantial number of children globally will benefit from pharmacologic treatments. It will be reasonable to extrapolate efficacy of most treatments from adult trials to children. Pediatric trials should focus on characterizing a treatment’s pharmacokinetics, optimal dose, and safety across the age spectrum. These trials should use an adaptive design to efficiently add or remove arms in what will be a rapidly evolving treatment landscape, and should involve a large number of sites across the globe in a collaborative effort to facilitate efficient implementation. All stakeholders must commit to equitable access to any effective, safe treatment for children everywhere.en_ZA
dc.description.urihttps://academic.oup.com/cid/article/72/6/1067/5864500?login=trueen_ZA
dc.description.versionPublishers versionen_ZA
dc.format.extent7 pagesen_ZA
dc.identifier.citationGarcia-Prats, A. J. et al. 2021. Coronavirus Disease 2019 (COVID-19) Pharmacologic Treatments for Children: Research Priorities and Approach to Pediatric Studies. Clinical infectious diseases, 72(6):1067–1073. doi:10.1093/cid/ciaa885en_ZA
dc.identifier.issn1537-6591 (online)en_ZA
dc.identifier.issn1058-4838 (print)en_ZA
dc.identifier.otherdoi:10.1093/cid/ciaa885en_ZA
dc.identifier.urihttp://hdl.handle.net/10019.1/125300en_ZA
dc.language.isoen_ZAen_ZA
dc.publisherOxford University Pressen_ZA
dc.rights.holderAuthors retain copyrighten_ZA
dc.subjectCOVID-19 (Disease)en_ZA
dc.subjectInfection in childrenen_ZA
dc.subjectClinical trialsen_ZA
dc.subjectPharmacokineticsen_ZA
dc.subjectInfectious diseasesen_ZA
dc.subjectDrugs -- Researchen_ZA
dc.titleCoronavirus disease 2019 (COVID-19) pharmacologic treatments for children : research priorities and approach to pediatric studiesen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
garcia_coronavirus_2020.pdf
Size:
208.2 KB
Format:
Adobe Portable Document Format
Description:
Download article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (Paediatrics and Child Health)